Novartis Financial Results – Q3 2026
Novartis announces the company’s financial results for the third quarter of 2026.
Latest news
Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
30 years of Novartis, powered by 250 years of innovation
Rooted in a legacy of scientific discovery, Novartis continues to advance breakthrough medicines that redefine the future of care for patients.
Annual reporting suite
Explore and download our Annual Report 2025, Report on Nonfinancial Matters 2025 and other reporting documents.